Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. We have significant market opportunities with a first-in-class molecule that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes.

In addition, we have a value-driven, fully out-licensed partnership with MedImmune for a second core program.

Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value.

Management Team

• John L. Armstrong, Jr.
• Michael Gast, M.D., Ph.D.
• Henry R. Wolfe, Ph.D.
• Leanne M. Kelly, CPA

Recent News:

• Genaera Corporation Announces Initiatives to Conserve Resources to Continue Development Efforts

  May 8th, 2008

• Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph

  April 8th, 2008

• Genaera Corporation Announces 2007 Financial Results

  March 31st, 2008

• Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting

  March 28th, 2008

Upcoming Events:

• American Diabetes Association Meeting
  New Orleans, LA

  June 6th, 2008 -- June 10th, 2008